Want to see FR:ALDVI full AI Analyst Report?
ALDVI Stock Chart & Stats
€0.92
-€0.05(-2.91%)
At close: 4:00 PM EDT
€0.92
-€0.05(-2.91%)
Day’s Range― - ―
52-Week Range€0.66 - €2.35
Previous CloseN/A
Volume71.90K
Average Volume (3M)135.05K
Market Cap
€11.51M
Enterprise Value€38.08
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)259.8
Beta0.12
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume96,178
30 Day Avg. Volume135,049
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€6.60M
Bulls Say, Bears Say
Bulls Say
Rare-disease SpecializationSpecialization in rare kidney and metabolic diseases gives Advicenne a clearly defined therapeutic focus and supports expertise around conditions with limited treatment options. Its marketed Sibnayal product provides an established commercial platform from which the company can build further disease-area growth.
Product Commercialization ModelCombining direct or distributor-based product sales with licensing and commercialization partnerships gives Advicenne multiple routes to monetize its therapies. This model can support geographic expansion while allowing partners to contribute market access and commercial execution in selected regions.
Improving Gross ProfitabilityThe shift to positive gross margin indicates that product-level economics improved in 2025, even though the company remains unprofitable overall. If maintained, stronger gross profitability could improve operating leverage and allow a greater share of future revenue growth to support fixed costs.
Bears Say
Negative Equity And Fragile Capital StructurePersistent negative equity materially weakens financial resilience and limits balance-sheet flexibility. Sizable debt relative to assets adds pressure to funding decisions and increases the company’s dependence on successful operations or additional financing to support its longer-term strategy.
Persistent Cash BurnOngoing negative operating and free cash flow shows that the business is not yet self-funding its operations. The renewed deterioration in 2025 increases reliance on external funding, which can constrain investment capacity and make execution more vulnerable if financing becomes less available.
Weak And Volatile ProfitabilitySmall, volatile revenue and continuing operating and net losses indicate that commercial scale has not yet translated into sustainable earnings. Negative growth in 2025 raises concern that the improved gross margin is insufficient to offset operating costs and establish durable profitability.
Advicenne SA News
ALDVI FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.66 and its highest was €2.35 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €11.51M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Apr 01, 2027 which is in 189 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Sep 17, 2026. The company reported €0.32 earnings per share for the quarter.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of €0.32 in its last earnings report. Following the earnings report the stock price went up 10.13%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in FR:ALDVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.